APTO News and Press, Aptose Biosciences Inc. From 12/10/21

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

HM43239 clinical update in AML after oral presentation at 2021 ASH Annual Meeting Luxeptinib clinical update in AML and B-cell cancers SAN DIEGO and TORONTO, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS), a clinical...

SAN DIEGO and TORONTO, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that the Aptose management team will be particip...

Aptose Biosciences Inc. (APTO) Q3 2021 Earnings Conference Call November 11, 2021, 5:00 PM ET Company Participants Susan Pietropaolo - Communications Representative Dr. William Rice - Chairman, President and CEO Dr. Jotin Marango - Senior Vice President, Chief Financial Officer and CBO Dr. Ra...

- Conference call and webcast at 5:00 pm ET today - - HM43239, myeloid kinome inhibitor with clinically validated activity added to pipeline - - HM43239 phase 1/2 study in AML advances to 200 mg dose - - Luxeptinib phase 1a/b studies in AML/MDS a...

Aptose Biosciences (NASDAQ:APTO) is scheduled to announce Q3 earnings results on Wednesday, November 10th, after market close. The consensus EPS Estimate is -$0.16 (-6.7% Y/Y) and the consensus Revenue Estimate is $0M Over the last 3 months, EPS estimates have seen 5 upward revisions and 0 do...

SAN DIEGO and TORONTO, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that clinical data for HM...

Aptose Biosciences (NASDAQ:APTO) has entered into an exclusive license agreement with Hanmi Pharmaceutical to develop and commercialize HM43239, designed to target a distinct constellation of kinases operative in myeloid malignancies, including SYK, FLT3, and others. Hanmi will receive a...

HM43239 delivers multiple complete responses (CRs) in diverse R/R AML patients Aptose to host conference call and webcast today at 9:00 am ET SAN DIEGO and TORONTO and SEOUL, South Korea, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS),...

SAN DIEGO and TORONTO, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, will report financial results for the quarter ended September 30...